Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

This phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 21 of each 28-day cycle in patients with relapsed and refractory multiple myeloma (RRMM). After four cycles, patients who progressed or had not achieved minim...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Richardson, Paul G., Siegel, David, Baz, Rachid, Kelley, Susan L., Munshi, Nikhil C., Laubach, Jacob, Sullivan, Daniel, Alsina, Melissa, Schlossman, Robert, Ghobrial, Irene M., Doss, Deborah, Loughney, Nora, McBride, Laura, Bilotti, Elizabeth, Anand, Palka, Nardelli, Lisa, Wear, Sandra, Larkins, Gail, Chen, Min, Zaki, Mohamad H., Jacques, Christian, Anderson, Kenneth C.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2013
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123324/
https://ncbi.nlm.nih.gov/pubmed/23243282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-08-450742
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares